Washington University is collaborating with biopharmaceutical company Pfizer Inc. on research to speed up the development of new drugs targeting certain diseases.
The university said Wednesday it’s the first Midwest academic institution to join the collaborative network for Pfizer’s Centers for Therapeutic Innovation. CTI brings together Pfizer scientists and patient foundations, and academic and National Institutes of Health researchers, to work together on drug discovery in broad areas of interest to the company.
The collaboration will focus on certain rare diseases, as well as on immunology and inflammation, oncology, neuroscience, and cardiovascular and metabolic diseases, university officials said. The program particularly will focus on large-molecule therapeutics and antibodies with the potential to treat multiple diseases.
Through the partnership, Washington University researchers can apply for funding for research projects targeting drug discovery. Projects will be selected by a joint steering committee comprised of Washington University researchers and Pfizer scientists. If a project is selected, the project team will have access to Pfizer’s resources, scientific equipment and collaboration with Pfizer scientists.
Read more: St. Louis Business Journal